Detalhe da pesquisa
1.
A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
Int J Cancer
; 150(11): 1889-1904, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35262190
2.
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Lancet Oncol
; 20(2): 239-253, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30660609
3.
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Br J Cancer
; 120(4): 387-397, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739911
4.
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Lancet
; 387(10026): 1405-1414, 2016 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26719230
5.
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Eur Respir J
; 48(3): 861-72, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27338193
6.
Second-line therapy in elderly patients with advanced nonsmall cell lung cancer.
Eur Respir J
; 43(1): 240-9, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24114964
7.
Study design and rationale for IFCT- 2203 TAXIO: A study that aims to evaluate the effectiveness of a first-line chemotherapy regimen without etoposide, combined with durvalumab, for patients with extensive disease small cell lung cancer.
Respir Med Res
; 86: 101113, 2024 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38843598
8.
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Lancet Oncol
; 13(3): 247-55, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22341744
9.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Lancet Oncol
; 13(3): 239-46, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22285168
10.
A Comparative Multicenter Cohort Study Evaluating the Long-Term Influence of the Strict Lockdown during the First COVID-19 Wave on Lung Cancer Patients (ARTEMISIA Trial).
Cancers (Basel)
; 15(24)2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38136275
11.
VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial.
Lung Cancer
; 182: 107287, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37393757
12.
Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).
Target Oncol
; 18(6): 905-914, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37966566
13.
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Lancet
; 378(9796): 1079-88, 2011 Sep 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-21831418
14.
Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial.
Lung Cancer
; 164: 84-90, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35051725
15.
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).
Lung Cancer
; 166: 107-113, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35257949
16.
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Lancet Reg Health Eur
; 22: 100492, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108315
17.
Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
J Immunother Cancer
; 10(10)2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36270733
18.
Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial.
Clin Cancer Res
; 28(18): 4018-4026, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35802649
19.
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Lancet Oncol
; 11(6): 521-9, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20493771
20.
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Cancers (Basel)
; 13(5)2021 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33801285